Jardiance (empagliflozin) is a prescription drug that ... your doctor may recommend increasing your dosage to the maximum: 25 mg taken once daily. help lower the risk of death in adults with ...
The EMPACT-MI trial found that giving Boehringer Ingelheim and Eli Lilly’s SGLT2 drug Jardiance (empagliflozin) within 14 days of an acute myocardial infarction (AMI) reduced the risk of a ...
Empagliflozin was originally approved for use in patients with diabetes, but investigators chose to study the drug based on earlier findings that it showed benefit in preventing active heart ...
ATLANTA, GA—Empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly), when given shortly after an acute MI, does not reduce the risk of subsequent heart failure (HF) hospitalization or death, results ...
Boehringer Ingelheim and Eli Lilly have reported data from the Phase III EMPACT-MI clinical trial of Jardiance (empagliflozin ...
Other data on acute MI at ACC will address whether heart attack survivors are helped by the SGLT2 inhibitor empagliflozin (Jardiance) in the EMPACT-MI trial. This trial also had approximately ...
US pharm major Eli Lilly (NYSE: LLY) and German partner Boehringer Ingelheim recently presented results of the Phase III EMPACT-MI trial, which examined patients treated with sodium-glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback